Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | WEE1 | P30291 | 7/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23364877 | 1.00 | MAP3K14 (0.32) | MAP3K14WEE1EGFRCYP3A4PLK1 | |
| SCHEMBL24881427 | 1.00 | MAP3K14 (0.32) | MAP3K14WEE1EGFRCYP3A4PLK1 | |
| SCHEMBL23364936 | 0.90 | NR3C1 (0.34) | MAP3K14WEE1 | |
| SCHEMBL25100755 | 0.90 | NR3C1 (0.34) | MAP3K14WEE1 | |
| SCHEMBL23364932 | 0.90 | NR3C1 (0.34) | MAP3K14WEE1 | |
| SCHEMBL25030489 | 0.89 | GRIN2D (0.33) | MAP3K14WEE1KDM4EALDH1A1 | |
| SCHEMBL24858484 | 0.87 | — | — | |
| SCHEMBL23364873 | 0.83 | MAP3K14 (0.38) | MAP3K14WEE1EGFRCYP3A4PLK1 | |
| SCHEMBL21334000 | 0.83 | MAP3K14 (0.32) | MAP3K14WEE1EGFRCYP3A4PLK1 | |
| SCHEMBL22532060 | 0.83 | MAP3K14 (0.38) | MAP3K14WEE1EGFRCYP3A4PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028363-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12410204-B2 | Chiral synthesis of a tertiary alcohol | RECURIUM IP HOLDINGS, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2023-07-27 | — | — | US | disclosed |
| WO-2023138362-A1 | WEE1 INHIBITOR, PREPARATION THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023030388-A1 | 5-FLUORO-7H-PYRROLO[2,3-D] PYRIMIDINES COMPOUND AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023280180-A1 | FUSED RING COMPOUND AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC | 2023-01-05 | — | — | US | disclosed |
| EP-4045486-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | Recurium IP Holdings, LLC (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021097139-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097139-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410204-B2 | Chiral synthesis of a tertiary alcohol | ADH1A, ADH1C, ADH5 | MAP3K14 755/4885WEE1 640/4885EGFR 2142/4885 |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | WEE1, WEE2, CCNE1 | MAP3K14 394/4885WEE1 1/4885EGFR 1387/4885 |
| US-20260028363-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | ADH1A, ADH1C, ADH5 | MAP3K14 873/4885WEE1 92/4885EGFR 717/4885 |
| US-20230002426-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | ADH1A, ADH1C, ADH5 | MAP3K14 755/4885WEE1 640/4885EGFR 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.